Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 172 clinical trials
Functional Analysis of BRCAness

identification of a larger group of patients that could benefit most from platinum based chemotherapy and maintenance treatment with a PARP inhibitor. We recently developed a robust ex vivo functional assay

  • 0 views
  • 09 Apr, 2021
  • 3 locations
Adjuvant Protontherapy of Cervical and Endometrial Carcinomas

fractions 5-6 times per week using active raster-scanning pencil beam proton radiation. Platinum-based chemotherapy can be administered if indicated. The primary endpoint of the study is the evaluation of

immunomodulator
cancer
pelvic radiation
carcinoma
  • 30 views
  • 21 Jan, 2021
Immunotherapy in Patient With Poor General Condition

), for metastatic NSCLC patients, after failure of a prior platinum-based chemotherapy. The approval was based on the results of phase III clinical trials in metastatic NSCLC. But all the trials

cancer
liver metastasis
platinum-based chemotherapy
growth factor
pd-l1
  • 7 views
  • 27 Jan, 2021
  • 20 locations
Durvalumab (MEDI4736) Plus Total Neoadjuvant Therapy (TNT) in Locally Advanced Rectal Cancer

The addition of durvalumab to total neoadjuvant therapy (TNT) in locally advanced rectal cancer may improve the pathological complete response rate. The induction platinum-based chemotherapy may

rectal surgery
carcinoma
oxaliplatin
chemoradiotherapy
leucovorin
  • 37 views
  • 23 Jan, 2021
  • 9 locations
Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX)

, many of them are not able to withstand a platinum-based chemotherapy. The addition of taxanes to the armamentarium of drugs improve the outcome in this group of patients. An alternative and better

  • 0 views
  • 02 Apr, 2021
  • 20 locations
Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance

resistance to ICIs monotherapies or ICI in combination with platinum-based chemotherapies, with experimental precision immunotherapies combined to Durvalumab in 2nd, 3rd or 4th line, in advanced NSCLC

serum bilirubin level
carcinoma
secondary malignant neoplasm of liver
atezolizumab
medi4736
  • 0 views
  • 09 Apr, 2021
  • 1 location
Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma

There is currently no standard treatment beyond first-line etoposide/platinum-based chemotherapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma

  • 0 views
  • 12 Mar, 2021
  • 4 locations
Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma

Background Thymoma and thymic carcinoma are diseases of the thymus. Platinum-based chemotherapy is the standard treatment for these diseases. But in many cases

  • 0 views
  • 21 Feb, 2021
  • 1 location
Hippocampal-Sparing Prophylactic Cranial Irradiation in Pathologically Nodal Positive Non-Small-Cell Lung Cancer

of adjuvant platinum-based chemotherapy. Radiotherapy dose will be 3000 cGy in 15 fractions during three weeks. Except for the administration of hippocampal-sparing PCI, patients assigned to the

  • 0 views
  • 18 Mar, 2021
  • 1 location
A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

regimen in patients with advanced NSCLC pretreated with non-platinum based chemotherapy. TS-1 (Jeil Pharmaceutical Co.,Ltd, Seoul, Korea) is an oral anticancer drug comprised of tegafur

  • 10 views
  • 07 Nov, 2020
  • 1 location